文献速递炎症性肠病胃肠动力与功能性疾病

系统综述与Meta分析:粪便钙卫蛋白在成人中鉴别炎症性肠病与肠易激综合征的诊断性能

Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
PubMed 文献 · Aliment Pharmacol Ther · 2023-10-12

该系统综述与Meta分析检索截至2023年1月1日的数据库,纳入17项研究共1956例患者,评估粪便钙卫蛋白鉴别成人炎症性肠病与肠易激综合征的诊断性能。汇总敏感度为85.8%(95%CI:78.3-91),特异度为91.7%(95%CI:84.5-95.7);在炎症性肠病患病率1%时,阴性预测值为99.8%,阳性预测值仅9%。

要点

  • 粪便钙卫蛋白鉴别炎症性肠病与肠易激综合征的汇总敏感度85.8%、特异度91.7%。
  • 患病率1%时阴性预测值99.8%,阳性预测值仅9%。
  • 西方国家敏感度88%高于东方国家73%,cut-off≤50 μg/g敏感度87%高于>50 μg/g的79%。

核心结论

  • 粪便钙卫蛋白是鉴别炎症性肠病与肠易激综合征的可靠检测。
  • 粪便钙卫蛋白在西方国家及cut-off≤50 μg/g时似乎具有更好的敏感度。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、Scopus和Cochrane Library数据库截至2023年1月1日。
  • 纳入标准为在成人中评估粪便钙卫蛋白鉴别炎症性肠病与肠易激综合征(肠易激综合征按Rome标准定义)诊断性能的研究,以结肠镜加组织学或影像学为参考标准。
  • 共纳入17项研究,总计1956例患者。
  • 采用随机效应双变量模型计算汇总敏感度、特异度及其95%置信区间。
  • 使用诊断准确性研究质量评估工具II(QUADAS-II)评估偏倚风险。

主要发现

  • 汇总敏感度为85.8%(95%CI:78.3-91),汇总特异度为91.7%(95%CI:84.5-95.7)。
  • 在炎症性肠病患病率1%时,阴性预测值为99.8%,阳性预测值仅为9%。
  • 亚组分析显示西方国家敏感度88% vs 东方国家73%,cut-off≤50 μg/g敏感度87% vs >50 μg/g 79%,特异度估计相似。
  • 所有研究均处于「高」或「不明确」偏倚风险。

关键数值与推荐

  • 以结肠镜加组织学或影像学为参考标准,粪便钙卫蛋白鉴别炎症性肠病与肠易激综合征的汇总敏感度85.8%(95%CI:78.3-91)、特异度91.7%(95%CI:84.5-95.7)。
  • 炎症性肠病患病率1%时,阴性预测值99.8%,阳性预测值9%。
  • 西方国家敏感度88% vs 东方国家73%,特异度估计相似。
  • cut-off≤50 μg/g敏感度87% vs >50 μg/g 79%,特异度估计相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有研究均处于「高」或「不明确」偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Symptoms of inflammatory bowel disease (IBD) often overlap with those of irritable bowel syndrome (IBS). AIM: To evaluate the diagnostic performance of faecal calprotectin in distinguishing patients with IBD from those with IBS METHODS: We searched MEDLINE, Embase, Scopus, and Cochrane Library databases up to 1 January 2023. Studies were included if they assessed the diagnostic performance of faecal calprotectin in distinguishing IBD from IBS (defined according to the Rome criteria) using colonoscopy with histology or radiology as reference standard in adults. We calculated summary sensitivity and specificity and their 95% confidence intervals (CI) using a random-effect bivariate model. The risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies II. RESULTS: We included 17 studies with a total of 1956 patients. The summary sensitivity was 85.8% (95% CI: 78.3-91), and the specificity was 91.7% (95% CI: 84.5-95.7). At a prevalence of IBD of 1%, the negative predictive value was 99.8%, while the positive predictive value was only 9%. Subgroup analyses showed a higher sensitivity in Western than in Eastern countries (88% vs 73%) and at a cut-off of ≤50 μg/g than at >50 μg/g (87% vs. 79%), with similar estimates of specificity. All studies were at "high" or "unclear" risk of bias. CONCLUSIONS: Faecal calprotectin is a reliable test in distinguishing patients with IBD from those with IBS. Faecal calprotectin seems to have a better sensitivity in Western countries and at a cut-off of ≤50 μg/g.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Dajti E, Frazzoni L, Iascone V, et al. Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults. Aliment Pharmacol Ther. 2023. PMID: 37823411. doi:10.1111/apt.17754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。